ストックスクリーナーアプリを入手
5.22
4.19%
0.21
プレマーケット:
5.49
0.27
+5.17%
前日終値:
$5.01
開ける：
$5.08
24時間の取引高:
312.02K
Relative Volume:
0.85
時価総額：
$72.02M
収益：
-
当期純損益:
$-56.20M
株価収益率:
-0.8392
EPS:
-6.22
ネットキャッシュフロー:
$-39.97M
1週間 パフォーマンス:
+11.78%
1か月 パフォーマンス:
+19.45%
6か月 パフォーマンス:
-53.93%
1年 パフォーマンス:
-55.38%
1日の値動き範囲:
$5.00
$5.48
1週間の範囲:
$4.63
$5.48
52週間の値動き範囲:
$4.21
$20.00
Annovis Bio Inc Stock (ANVS) Company Profile
名前
Annovis Bio Inc
セクター
電話
484-875-3192
住所
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
ANVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
5.22 | 72.02M | 0 | -56.20M | -39.97M | -6.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-25 | アップグレード | Maxim Group | Hold → Buy |
| 2023-12-29 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
Annovis Bio Inc (ANVS) 最新ニュース
Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap - MSN
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Annovis Bio granted U.S. patent covering buntanetap - Yahoo Finance
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - GlobeNewswire
Annovis Bio secures US patent for brain injury treatment By Investing.com - Investing.com Nigeria
Annovis Bio secures US patent for brain injury treatment - Investing.com India
Annovis Bio Secures Key U.S. Patent for Brain Injury Treatment Breakthrough Buntanetap - StockTitan
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MyChesCo
Geode Capital Management LLC Has $799,000 Position in Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Given Average Rating of “Buy” by Analysts - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives $31.40 Average Price Target from Analysts - MarketBeat
Annovis Bio Stock Among Retail's Top Draws After FDA Nod For Final Phase 3 Alzheimer’s Study Protocol - MSN
FDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s Study - MSN
FDA approves Annovis Bio's updated Alzheimer's trial protocol By Investing.com - Investing.com Canada
FDA approves Annovis Bio's revised Phase 3 AD study protocol By Investing.com - Investing.com Canada
Annovis Bio stock slips after Alzheimer’s update (ANVS:NYSE) - Seeking Alpha
Annovis Bio, Inc. Announces FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer?s Disease Study, Streamlining Development Pathway - Marketscreener.com
FDA approves Annovis Bio's updated Alzheimer's trial protocol - Investing.com
FDA approves Annovis Bio's revised Phase 3 AD study protocol - Investing.com
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway - GlobeNewswire
Annovis Bio Streamlines Phase 3 Alzheimer's Trial After FDA Approval, Accelerates Path to Market - StockTitan
State Street Corp Increases Stock Holdings in Annovis Bio, Inc. (NYSE:ANVS) - Defense World
How To Trade (ANVS) - Stock Traders Daily
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
Annovis Bio (NYSE: ANVS) Eyes Opportunities Beyond ‘Year Of Significant Progress’ - Barchart
Annovis Bio (NYSE: ANVS) Committed To Ensuring Highest Standards In Buntanetap Trials - Barchart
Annovis Bio stock hits 52-week low at $4.52 amid market challenges - Investing.com Canada
When (ANVS) Moves Investors should Listen - Stock Traders Daily
Annovis Bio (NYSE: ANVS) Eyes Clear Path Forward For Buntanetap - Barchart
Annovis Bio, Inc. (NYSE:ANVS) Short Interest Update - MarketBeat
Royal Bank of Canada (RY-N) QuotePress Release - The Globe and Mail
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Annovis Bio (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Investor Webcast - Barchart
Annovis Bio, Inc. Appoints William Fricker to Serve as Chief Financial Officer on an Interim Basis - Marketscreener.com
Annovis Bio Announces Investor Webcast to Share Key Updates - MSN
Annovis Bio Advances Alzheimer’s and Parkinson’s Drug Trials - TipRanks
Form 424B5 Annovis Bio, Inc. - StreetInsider.com
Annovis Bio appoints interim CFO By Investing.com - Investing.com Nigeria
7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline - BioSpace
Annovis Bio appoints interim CFO - Investing.com
Annovis Bio Appoints William Fricker as Interim CFO - TipRanks
(ANVS) On The My Stocks Page - Stock Traders Daily
Annovis Bio (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace - Barchart
We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate - Simply Wall St
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace - GlobeNewswire
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s - The Bakersfield Californian
Annovis Bio Inc (ANVS) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):